U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H22FN3O2
Molecular Weight 379.4274
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DROPERIDOL

SMILES

FC1=CC=C(C=C1)C(=O)CCCN2CCC(=CC2)N3C(=O)NC4=CC=CC=C34

InChI

InChIKey=RMEDXOLNCUSCGS-UHFFFAOYSA-N
InChI=1S/C22H22FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-11H,3,6,12-15H2,(H,24,28)

HIDE SMILES / InChI

Molecular Formula C22H22FN3O2
Molecular Weight 379.4274
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/droperidol.html

Droperidol produces marked tranquilization and sedation. It allays apprehension and provides a state of mental detachment and indifference while maintaining a state of reflex alertness. Droperidol produces an antiemetic effect as evidenced by the antagonism of apomorphine in dogs. It lowers the incidence of nausea and vomiting during surgical procedures and provides antiemetic protection in the postoperative period. Droperidol potentiates other CNS depressants. It produces mild alpha-adrenergic blockade, peripheral vascular dilatation and reduction of the pressor effect of epinephrine. It can produce hypotension and decreased peripheral vascular resistance and may decrease pulmonary arterial pressure (particularly if it is abnormally high). It may reduce the incidence of epinephrine-induced arrhythmias, but it does not prevent other cardiac arrhythmias. The exact mechanism of action is unknown, however, droperidol causes a CNS depression at subcortical levels of the brain, midbrain, and brainstem reticular formation. It may antagonize the actions of glutamic acid within the extrapyramidal system. It may also inhibit cathecolamine receptors and the reuptake of neurotransmiters and has strong central antidopaminergic action and weak central anticholinergic action. It can also produce ganglionic blockade and reduced affective response. The main actions seem to stem from its potent Dopamine (2) receptor antagonism with minor antagonistic effects on alpha-1 adrenergic receptors as well. Droperidol is used to produce tranquilization and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures.

CNS Activity

Curator's Comment: Droperidol causes a CNS depression at subcortical levels of the brain, midbrain, and brainstem reticular formation.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
INAPSINE

Approved Use

Droperidol injection is indicated to reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures.

Launch Date

1970
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
6.5 μg/L
0.02 mg/kg single, nasal
dose: 0.02 mg/kg
route of administration: Nasal
experiment type: SINGLE
co-administered:
DROPERIDOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
26.6 μg/L
0.02 mg/kg single, intravenous
dose: 0.02 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DROPERIDOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
18.7 μg × h/L
0.02 mg/kg single, nasal
dose: 0.02 mg/kg
route of administration: Nasal
experiment type: SINGLE
co-administered:
DROPERIDOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
40 μg × h/L
0.02 mg/kg single, intravenous
dose: 0.02 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DROPERIDOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.4 h
0.02 mg/kg single, nasal
dose: 0.02 mg/kg
route of administration: Nasal
experiment type: SINGLE
co-administered:
DROPERIDOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2.1 h
0.02 mg/kg single, intravenous
dose: 0.02 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DROPERIDOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.4 mg/kg multiple, oral
unhealthy, 2-9 years
Disc. AE: QT interval prolonged...
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
n = 61
Health Status: unhealthy
Condition: acute migraine headache
Age Group: 42 ± 10.0 years
Sex: M+F
Population Size: 61
Sources:
Other AEs: Asthenia, Chills...
Other AEs:
Asthenia (24.6%)
Chills (3.3%)
Anorexia (3.3%)
Akathisia (16.4%)
Anxiety (27.9%)
Confusion (3.3%)
Dizziness (9.8%)
Dry mouth (9.8%)
Nervousness (4.9%)
Paresthesia (3.3%)
Somnolence (24.6%)
Tremor (1.6%)
Pharyngitis (4.9%)
Rhinitis (4.9%)
Sweaty (8.2%)
Sources:
2.5 mg multiple, intravenous (starting)
unhealthy
Disc. AE: Torsades de pointes...
AEs

AEs

AESignificanceDosePopulation
QT interval prolonged Disc. AE
0.4 mg/kg multiple, oral
unhealthy, 2-9 years
Tremor 1.6%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
n = 61
Health Status: unhealthy
Condition: acute migraine headache
Age Group: 42 ± 10.0 years
Sex: M+F
Population Size: 61
Sources:
Akathisia 16.4%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
n = 61
Health Status: unhealthy
Condition: acute migraine headache
Age Group: 42 ± 10.0 years
Sex: M+F
Population Size: 61
Sources:
Asthenia 24.6%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
n = 61
Health Status: unhealthy
Condition: acute migraine headache
Age Group: 42 ± 10.0 years
Sex: M+F
Population Size: 61
Sources:
Somnolence 24.6%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
n = 61
Health Status: unhealthy
Condition: acute migraine headache
Age Group: 42 ± 10.0 years
Sex: M+F
Population Size: 61
Sources:
Anxiety 27.9%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
n = 61
Health Status: unhealthy
Condition: acute migraine headache
Age Group: 42 ± 10.0 years
Sex: M+F
Population Size: 61
Sources:
Anorexia 3.3%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
n = 61
Health Status: unhealthy
Condition: acute migraine headache
Age Group: 42 ± 10.0 years
Sex: M+F
Population Size: 61
Sources:
Chills 3.3%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
n = 61
Health Status: unhealthy
Condition: acute migraine headache
Age Group: 42 ± 10.0 years
Sex: M+F
Population Size: 61
Sources:
Confusion 3.3%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
n = 61
Health Status: unhealthy
Condition: acute migraine headache
Age Group: 42 ± 10.0 years
Sex: M+F
Population Size: 61
Sources:
Paresthesia 3.3%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
n = 61
Health Status: unhealthy
Condition: acute migraine headache
Age Group: 42 ± 10.0 years
Sex: M+F
Population Size: 61
Sources:
Nervousness 4.9%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
n = 61
Health Status: unhealthy
Condition: acute migraine headache
Age Group: 42 ± 10.0 years
Sex: M+F
Population Size: 61
Sources:
Pharyngitis 4.9%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
n = 61
Health Status: unhealthy
Condition: acute migraine headache
Age Group: 42 ± 10.0 years
Sex: M+F
Population Size: 61
Sources:
Rhinitis 4.9%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
n = 61
Health Status: unhealthy
Condition: acute migraine headache
Age Group: 42 ± 10.0 years
Sex: M+F
Population Size: 61
Sources:
Sweaty 8.2%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
n = 61
Health Status: unhealthy
Condition: acute migraine headache
Age Group: 42 ± 10.0 years
Sex: M+F
Population Size: 61
Sources:
Dizziness 9.8%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
n = 61
Health Status: unhealthy
Condition: acute migraine headache
Age Group: 42 ± 10.0 years
Sex: M+F
Population Size: 61
Sources:
Dry mouth 9.8%
8.25 mg single, intramuscular
Highest studied dose
Dose: 8.25 mg
Route: intramuscular
Route: single
Dose: 8.25 mg
Sources:
unhealthy, 42 ± 10.0 years
n = 61
Health Status: unhealthy
Condition: acute migraine headache
Age Group: 42 ± 10.0 years
Sex: M+F
Population Size: 61
Sources:
Torsades de pointes Disc. AE
2.5 mg multiple, intravenous (starting)
unhealthy
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Warnings strengthened on tranquilizer inapsine (Droperidol).
2001 Dec 18
Evaluation of droperidol in the acutely agitated child or adolescent.
2001 Nov
Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.
2002
Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro-Brazil: a prevalence study.
2002
A placebo-controlled, randomized trial of droperidol versus metoclopramide for outpatients undergoing gynecological laparoscopy under conscious sedation.
2002 Apr
Use of sevoflurane during cardiopulmonary bypass decreases incidence of awareness.
2002 Apr
Droperidol inhibits GABA(A) and neuronal nicotinic receptor activation.
2002 Apr
Droperidol: cardiovascular toxicity and deaths.
2002 Apr 2
P6 acupoint injections are as effective as droperidol in controlling early postoperative nausea and vomiting in children.
2002 Aug
The black box warning.
2002 Fall
[Continuous epidural administration of droperidol to prevent postoperative nausea and vomiting].
2002 Feb
[Prophylaxis of Postoperative Nausea and Vomiting FollowingGynaecological Laparoscopy].
2002 Jan
[Droperidol causes multifocal ventricular dysrhythmias].
2002 Jan
A randomized clinical trial to assess the efficacy of intramuscular droperidol for the treatment of acute migraine headache.
2002 Jan
Premedication, preparation, and surveillance.
2002 Jan
Effects of sevoflurane on electrocorticography in patients with intractable temporal lobe epilepsy.
2002 Jan
Monocomponent chemoembolization in oral and oropharyngeal cancer using an aqueous crystal suspension of cisplatin.
2002 Jan 21
The rise and withdrawal of droperidol.
2002 Jul
Antiemetic effects of granisetron, droperidol and dexamethasone in otologic surgery.
2002 Jul
The FDA droperidol warning: is it justified?
2002 Jul
Droperidol "box warning" warrants scrutiny.
2002 Jul
FDA "black box" warning regarding use of droperidol for postoperative nausea and vomiting: is it justified?
2002 Jul
Dolasetron decreases postoperative nausea and vomiting after breast surgery.
2002 Jul-Aug
Evaluation of postural stability after low-dose droperidol in outpatients undergoing gynaecological dilatation and curettage procedure.
2002 Jun
Gateways to Clinical Trials. June 2002.
2002 Jun
Four-step local anesthesia and sedation for thoracoscopic diagnosis and management of pleural diseases.
2002 Jun
Intramuscular droperidol versus intramuscular dimenhydrinate for the treatment of acute peripheral vertigo in the emergency department: a randomized clinical trial.
2002 Jun
Droperidol--behind the black box warning.
2002 Jun
Rapid tranquillisation: time for a reappraisal of options for parenteral therapy.
2002 Jun
[Effects of preincisional epidural administration of lidocaine and fentanyl on postoperative pain management following hysterectomy].
2002 Jun 10
Arrhythmias from droperidol?
2002 Jun 10
Derivative spectrophotometric determination of droperidol in presence of parabens.
2002 Jun 20
Continuous epidural, not intravenous, droperidol inhibits pruritus, nausea, and vomiting during epidural morphine analgesia.
2002 Mar
Superior prolonged antiemetic prophylaxis with a four-drug multimodal regimen - comparison with propofol or placebo.
2002 Mar
Inapsine. Weighing the risk of fatal arrhythmias.
2002 Mar
Treatment patterns of isolated benign headache in US emergency departments.
2002 Mar
Black-box warning for droperidol surprises pharmacists.
2002 Mar 15
Comparison of granisetron and ramosetron for the prevention of nausea and vomiting after thyroidectomy.
2002 May
Using imprecise probabilities to address the questions of inference and decision in randomized clinical trials.
2002 May
Oral ondansetron, tropisetron or metoclopramide to prevent postoperative nausea and vomiting: a comparison in high-risk patients undergoing thyroid or parathyroid surgery.
2002 May
Psychotropic drugs and the ECG: focus on the QTc interval.
2002 May
Effects of clonidine on postoperative nausea and vomiting in breast cancer surgery.
2002 May
LC determination and degradation study of droperidol.
2002 May 15
Effect of intravenous droperidol on intraocular pressure and retrobulbar hemodynamics.
2002 May-Jun
Acute dystonia by droperidol during intravenous patient-controlled analgesia in young patients.
2002 Oct
Droperidol: a cost-effective antiemetic for over thirty years.
2002 Oct
Effects of anesthesia on efferent-mediated adaptation of the DPOAE.
2002 Sep
The addition of antiemetics to the morphine solution in patient controlled analgesia syringes used by children after an appendicectomy does not reduce the incidence of postoperative nausea and vomiting.
2002 Sep
Continuum of care: stabilizing the acutely agitated patient.
2002 Sep 1
Low-dose droperidol.
2002 Sep 3
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Intravenous or Intramuscular
Dosage: The dosage should be individualized. Factors to be considered in determining dose are age, body weight, physical status, underlying pathological condition, use of other drugs, the type of anesthesia to be used, and the surgical procedure involved. Vital signs and ECG should be monitored closely. Maximum Dosage: The maximum recommended initial dose is 2.5 mg IM or slow IV. Additional 1.25 mg doses of droperidol may be administered to achieve the desired effect. The additional doses should be administered with caution and only if the potential benefit outweighs the potential risk.
Route of Administration: Intravenous
Droperidol (10(-7) M) caused vasodilator effect (approximately 20% of vasorelaxation compared with maximal vasorelaxation induced by papaverine [3 x 10(-4) M] in rat vascular smooth muscle cells.
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:31:24 GMT 2023
Edited
by admin
on Sat Dec 16 16:31:24 GMT 2023
Record UNII
O9U0F09D5X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DROPERIDOL
EP   GREEN BOOK   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
R-4749
Code English
NSC-169874
Code English
DROPERIDOL [VANDF]
Common Name English
DROPERIDOL [ORANGE BOOK]
Common Name English
MCN-JR-4749
Code English
DROPERIDOL [GREEN BOOK]
Common Name English
DROPERIDOL [USP-RS]
Common Name English
INNOVAR COMPONENT DROPERIDOL
Common Name English
DROPERIDOL [MART.]
Common Name English
DROPERIDOL [USP MONOGRAPH]
Common Name English
Droperidol [WHO-DD]
Common Name English
1-(1-(3-(P-FLUOROBENZOYL)PROPYL)-1,2,3,6-TETRAHYDRO-4-PYRIDYL)-2-BENZIMIDAZOLINONE
Common Name English
DROPERIDOL [HSDB]
Common Name English
DROPERIDOL [USAN]
Common Name English
DROPERIDOL COMPONENT OF INNOVAR
Common Name English
DROPERIDOL [JAN]
Common Name English
2H-BENZIMIDAZOL-2-ONE, 1-(1-(4-(4-FLUOROPHENYL)-4-OXOBUTYL)-1,2,3,6-TETRAHYDRO-4-PYRIDINYL)-1,3-DIHYDRO-
Systematic Name English
droperidol [INN]
Common Name English
DROPERIDOL [MI]
Common Name English
INAPSINE
Brand Name English
DROPERIDOL [EP MONOGRAPH]
Common Name English
DROLEPTAN
Brand Name English
Classification Tree Code System Code
WHO-ATC N05AD08
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
CFR 21 CFR 522.800
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
LIVERTOX 332
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
NCI_THESAURUS C323
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
NDF-RT N0000175800
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
NDF-RT N0000175799
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
WHO-VATC QN05AD08
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
WHO-ATC N01AX01
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
Code System Code Type Description
MESH
D004329
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
PRIMARY
DRUG CENTRAL
966
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
PRIMARY
CHEBI
4717
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
PRIMARY
DRUG BANK
DB00450
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
PRIMARY
CAS
548-73-2
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
PRIMARY
ECHA (EC/EINECS)
208-957-8
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
PRIMARY
NCI_THESAURUS
C458
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
PRIMARY
RS_ITEM_NUM
1229001
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
PRIMARY
WIKIPEDIA
Droperidol
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
PRIMARY
LACTMED
Droperidol
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
PRIMARY
EVMPD
SUB06410MIG
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
PRIMARY
HSDB
3320
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
PRIMARY
RXCUI
3648
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
PRIMARY RxNorm
MERCK INDEX
m4769
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
PRIMARY Merck Index
FDA UNII
O9U0F09D5X
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
PRIMARY
NSC
169874
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
PRIMARY
IUPHAR
7172
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
PRIMARY
ChEMBL
CHEMBL1108
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
PRIMARY
INN
1609
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
PRIMARY
EPA CompTox
DTXSID6022973
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
PRIMARY
SMS_ID
100000081007
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
PRIMARY
PUBCHEM
3168
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
PRIMARY
DAILYMED
O9U0F09D5X
Created by admin on Sat Dec 16 16:31:25 GMT 2023 , Edited by admin on Sat Dec 16 16:31:25 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC